TheStreet’s top biotech stock ace, Adam Feuerstein, has culled through a mountain of releases and reports to come up with the 10 most closely-watched trial announcements expected in the second half of the year.

His list includes: Ariad’s Phase III data for the sarcoma drug ridaforolimus, which Merck licensed; AstraZeneca’s zibotentan, which hopes to answer the question about who has the next Provenge to offer the market; as well as mid-stage data on BioMarin’s Peg-Pal for phenylketonuria, with data due out this quarter.

Go to the report for all 10 trials to watch. As Feuerstein notes, it’s relatively easy to track drug approval schedules, but data releases can be hard to keep a tab on. Win or lose, the data is bound to either juice or poison a stock price.

- here’s the report from TheStreet

Related Articles:
Merck takes control of Ariad cancer program in $583M deal
AstraZeneca outlines deep cuts in global R&D ops
Resignation sparks buyout rumors at BioMarin